Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1174

1.

Endotracheal or Endobronchial Metastasis of Lung Squamous Cell Carcinoma.

Iijima Y, Hirotsu Y, Amemiya K, Higuchi R, Nakagomi T, Goto T, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Miyashita Y, Omata M.

J Bronchology Interv Pulmonol. 2019 Oct;26(4):e46-e50. doi: 10.1097/LBR.0000000000000595. No abstract available.

PMID:
31569101
2.

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.

Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M.

Hepatol Int. 2019 Sep 20. doi: 10.1007/s12072-019-09988-7. [Epub ahead of print]

PMID:
31541423
3.

Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer.

Hirotsu Y, Yokoyama H, Amemiya K, Hagimoto T, Daimon H, Hosaka K, Oyama T, Mochizuki H, Omata M.

Cancer Sci. 2019 Oct;110(10):3235-3243. doi: 10.1111/cas.14155. Epub 2019 Aug 10.

4.

Publisher Correction: DNA demethylation is associated with malignant progression of lower-grade gliomas.

Nomura M, Saito K, Aihara K, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Tanaka S, Takayanagi S, Otani R, Nejo T, Hana T, Takahashi S, Kitagawa Y, Omata M, Higuchi F, Nakamura T, Muragaki Y, Narita Y, Nagane M, Nishikawa R, Ueki K, Saito N, Aburatani H, Mukasa A.

Sci Rep. 2019 May 23;9(1):7935. doi: 10.1038/s41598-019-43790-7.

5.

Clinical Implications of Noncoding Indels in the Surfactant-Encoding Genes in Lung Cancer.

Nakagomi T, Hirotsu Y, Goto T, Shikata D, Yokoyama Y, Higuchi R, Otake S, Amemiya K, Oyama T, Mochizuki H, Omata M.

Cancers (Basel). 2019 Apr 17;11(4). pii: E552. doi: 10.3390/cancers11040552.

6.

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.

Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M.

Int J Mol Sci. 2019 Mar 18;20(6). pii: E1358. doi: 10.3390/ijms20061358. Review.

7.

DNA demethylation is associated with malignant progression of lower-grade gliomas.

Nomura M, Saito K, Aihara K, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Tanaka S, Takayanagi S, Otani R, Nejo T, Hana T, Takahashi S, Kitagawa Y, Omata M, Higuchi F, Nakamura T, Muragaki Y, Narita Y, Nagane M, Nishikawa R, Ueki K, Saito N, Aburatani H, Mukasa A.

Sci Rep. 2019 Feb 13;9(1):1903. doi: 10.1038/s41598-019-38510-0. Erratum in: Sci Rep. 2019 May 23;9(1):7935.

8.

Validation of Tokyo Guideline 2013 as Treatment of Acute Cholecystitis by Real World Data.

Harai S, Mochizuki H, Kojima Y, Nakagomi K, Yoshimura D, Takaoka S, Hosoda K, Suzuki Y, Omata M.

Dig Dis. 2019;37(4):303-308. doi: 10.1159/000496738. Epub 2019 Feb 7.

PMID:
30731461
9.

Deficiency of mismatch repair genes is less frequently observed in signet ring cell compared with non-signet ring cell gastric cancer.

Hirotsu Y, Mochizuki H, Amemiya K, Ohyama H, Yoshimura D, Amano H, Miura Y, Ashizawa H, Nakagomi K, Takaoka S, Hosoda K, Suzuki Y, Oyama T, Hada M, Kojima Y, Omata M.

Med Oncol. 2019 Jan 29;36(3):23. doi: 10.1007/s12032-019-1246-4.

PMID:
30694393
10.

The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.

Obi S, Sato T, Sato S, Kanda M, Tokudome Y, Kojima Y, Suzuki Y, Hosoda K, Kawai T, Kondo Y, Isomura Y, Ohyama H, Nakagomi K, Ashizawa H, Miura Y, Amano H, Mochizuki H, Omata M.

Hepatol Int. 2019 Mar;13(2):199-204. doi: 10.1007/s12072-019-09929-4. Epub 2019 Jan 22.

PMID:
30671808
11.

Molecular subtype switching in early-stage gastric cancers with multiple occurrences.

Takaoka S, Hirotsu Y, Ohyama H, Mochizuki H, Amemiya K, Oyama T, Ashizawa H, Yoshimura D, Nakagomi K, Hosoda K, Suzuki Y, Kojima Y, Omata M.

J Gastroenterol. 2019 Aug;54(8):674-686. doi: 10.1007/s00535-019-01547-z. Epub 2019 Jan 21.

PMID:
30666417
12.

Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.

Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M.

J Obstet Gynaecol Res. 2019 Mar;45(3):743-747. doi: 10.1111/jog.13851. Epub 2018 Nov 22.

PMID:
30565790
13.

APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Yokosuka O, Sarin SK, Omata M.

Hepatol Int. 2019 Mar;13(2):103-109. doi: 10.1007/s12072-018-9915-5. Epub 2018 Dec 11.

14.

Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3.

Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Otake S, Amemiya K, Oyama T, Mochizuki H, Omata M.

Cancers (Basel). 2018 Nov 30;10(12). pii: E478. doi: 10.3390/cancers10120478.

15.

Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues.

Amemiya K, Hirotsu Y, Oyama T, Omata M.

Clin Chim Acta. 2019 Jan;488:129-134. doi: 10.1016/j.cca.2018.11.002. Epub 2018 Nov 3.

PMID:
30395866
16.

Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.

Ooka Y, Miho K, Shuntaro O, Nakamura M, Ogasawara S, Suzuki E, Yasui S, Chiba T, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N, Mochizuki H, Omata M.

Hepatol Int. 2018 Nov;12(6):523-530. doi: 10.1007/s12072-018-9895-5. Epub 2018 Sep 21.

PMID:
30242733
17.

Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.

Iijima Y, Hirotsu Y, Mochizuki H, Amemiya K, Oyama T, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Miyashita Y, Omata M.

Clin Lung Cancer. 2018 Nov;19(6):e843-e847. doi: 10.1016/j.cllc.2018.07.002. Epub 2018 Jul 26. No abstract available.

PMID:
30122430
18.

HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.

Wei L, Omata M, Lim YS, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-Oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han KH, Mizokami M, Duan Z.

Antiviral Res. 2018 Oct;158:178-184. doi: 10.1016/j.antiviral.2018.08.001. Epub 2018 Aug 16.

PMID:
30120954
19.

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients.

Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A, Oryu M, Himoto T, Nishitsuji H, Shimotohno K, Omata M, Masaki T.

Int J Mol Sci. 2018 Jul 2;19(7). pii: E1940. doi: 10.3390/ijms19071940.

20.

Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach.

Goto T, Hirotsu Y, Amemiya K, Mochizuki H, Omata M.

Cancers (Basel). 2018 Jun 22;10(7). pii: E212. doi: 10.3390/cancers10070212. Review.

21.

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology.

Amemiya K, Hirotsu Y, Oyama T, Omata M.

J Vis Exp. 2018 Mar 21;(133). doi: 10.3791/56943.

PMID:
29630047
22.

New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.

Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Amemiya K, Okimoto K, Oyama T, Mochizuki H, Omata M.

Oncotarget. 2018 Jan 31;9(12):10635-10649. doi: 10.18632/oncotarget.24365. eCollection 2018 Feb 13.

23.

Influence of NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines.

Kojima Y, Hirotsu Y, Omata W, Sugimori M, Takaoka S, Ashizawa H, Nakagomi K, Yoshimura D, Hosoda K, Suzuki Y, Mochizuki H, Omata M.

World J Gastroenterol. 2018 Jan 28;24(4):511-518. doi: 10.3748/wjg.v24.i4.511.

24.

Simultaneous detection of genetic and copy number alterations in BRCA1/2 genes.

Hirotsu Y, Ooka Y, Sakamoto I, Nakagomi H, Omata M.

Oncotarget. 2017 Dec 6;8(70):114463-114473. doi: 10.18632/oncotarget.22962. eCollection 2017 Dec 29.

25.

Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases.

Nagano H, Obi S, Hatano E, Kaneko S, Kanai F, Omata M, Tsuji A, Itamoto T, Yamamoto K, Tanaka M, Kubo S, Hirata K, Nakamura H, Tomimaru Y, Yamanaka T, Kojima S, Monden M.

Hepatol Res. 2018 Aug;48(9):717-726. doi: 10.1111/hepr.13067. Epub 2018 Mar 12.

PMID:
29377364
26.

Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer.

Nakagomi H, Mochizuki H, Inoue M, Hirotsu Y, Amemiya K, Sakamoto I, Nakagomi S, Kubota T, Omata M.

Cancer Sci. 2018 Feb;109(2):453-461. doi: 10.1111/cas.13464. Epub 2018 Jan 17.

27.

Detection of tumor-derived DNA dispersed in the airway improves the diagnostic accuracy of bronchoscopy for lung cancer.

Goto T, Hirotsu Y, Nakagomi T, Shikata D, Yokoyama Y, Amemiya K, Tsutsui T, Kakizaki Y, Oyama T, Mochizuki H, Miyashita Y, Omata M.

Oncotarget. 2017 May 24;8(45):79404-79413. doi: 10.18632/oncotarget.18159. eCollection 2017 Oct 3.

28.

Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report.

Takano A, Hirotsu Y, Amemiya K, Nakagomi H, Oishi N, Oyama T, Mochizuki H, Omata M.

Oncol Lett. 2017 Oct;14(4):4428-4432. doi: 10.3892/ol.2017.6786. Epub 2017 Aug 22.

29.

Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.

Iijima Y, Hirotsu Y, Amemiya K, Ooka Y, Mochizuki H, Oyama T, Nakagomi T, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Goto T, Miyashita Y, Omata M.

Eur J Cancer. 2017 Nov;86:349-357. doi: 10.1016/j.ejca.2017.09.004. Epub 2017 Nov 5.

PMID:
29078173
30.

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.

Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R.

Clin Cancer Res. 2018 Jan 1;24(1):73-83. doi: 10.1158/1078-0432.CCR-16-2433. Epub 2017 Oct 10.

31.

Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood.

Goto T, Hirotsu Y, Amemiya K, Nakagomi T, Shikata D, Yokoyama Y, Okimoto K, Oyama T, Mochizuki H, Omata M.

Oncotarget. 2017 Jul 25;8(35):59268-59281. doi: 10.18632/oncotarget.19538. eCollection 2017 Aug 29.

32.

Elucidation of radiation-resistant clones by a serial study of intratumor heterogeneity before and after stereotactic radiotherapy in lung cancer.

Nakagomi T, Goto T, Hirotsu Y, Shikata D, Amemiya K, Oyama T, Mochizuki H, Omata M.

J Thorac Dis. 2017 Jul;9(7):E598-E604. doi: 10.21037/jtd.2017.06.02.

33.

Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.

Otani R, Mukasa A, Shin M, Omata M, Takayanagi S, Tanaka S, Ueki K, Saito N.

J Neurosurg. 2018 May;128(5):1428-1437. doi: 10.3171/2016.12.JNS161444. Epub 2017 Jul 28.

PMID:
28753115
34.

Periaortitis induced by epirubicin and cyclophosphamide for a patient with advanced breast cancer.

Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, Yamamoto A, Takano A, Miyasaka Y, Yasutome M, Hada M, Omata M.

Int Cancer Conf J. 2017 Jul 11;6(4):180-183. doi: 10.1007/s13691-017-0302-1. eCollection 2017 Oct.

35.

Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days.

Iijima Y, Hirotsu Y, Amemiya K, Higashi S, Miyashita Y, Omata M.

Respir Med Case Rep. 2017 Jun 5;22:31-33. doi: 10.1016/j.rmcr.2017.05.015. eCollection 2017.

36.

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK.

Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15. Review.

37.

Unexpectedly low frequency of BRCA1/2 deleterious mutations in Japanese patients with breast cancer.

Sakamoto I, Nakagomi H, Okimoto K, Inoue M, Hirotsu Y, Amemiya K, Mochizuki H, Omata M.

Breast J. 2018 Jan;24(1):96-98. doi: 10.1111/tbj.12849. Epub 2017 Jun 8. No abstract available.

PMID:
28597494
38.

Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile.

Goto T, Hirotsu Y, Mochizuki H, Nakagomi T, Shikata D, Yokoyama Y, Oyama T, Amemiya K, Okimoto K, Omata M.

Oncotarget. 2017 May 9;8(19):31133-31143. doi: 10.18632/oncotarget.16096.

39.

PALB2 mutation in a woman with bilateral breast cancer: A case report.

Nakagomi H, Hirotsu Y, Okimoto K, Sakamoto I, Amemiya K, Nakagomi S, Kubota T, Mochizuki H, Omata M.

Mol Clin Oncol. 2017 Apr;6(4):556-560. doi: 10.3892/mco.2017.1189. Epub 2017 Mar 9.

40.

Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system.

Takayanagi S, Mukasa A, Tanaka S, Nomura M, Omata M, Yanagisawa S, Yamamoto S, Ichimura K, Nakatomi H, Ueki K, Aburatani H, Saito N.

Neuro Oncol. 2017 Sep 1;19(9):1228-1236. doi: 10.1093/neuonc/nox034.

41.

Analysis of significantly mutated genes as a clinical tool for the diagnosis in a case of lung cancer.

Miyashita Y, Hirotsu Y, Tsutsui T, Higashi S, Sogami Y, Kakizaki Y, Goto T, Amemiya K, Oyama T, Omata M.

Respir Med Case Rep. 2017 Feb 17;20:171-175. doi: 10.1016/j.rmcr.2017.02.008. eCollection 2017.

42.

Genetic and epigenetic stability of oligodendrogliomas at recurrence.

Aihara K, Mukasa A, Nagae G, Nomura M, Yamamoto S, Ueda H, Tatsuno K, Shibahara J, Takahashi M, Momose T, Tanaka S, Takayanagi S, Yanagisawa S, Nejo T, Takahashi S, Omata M, Otani R, Saito K, Narita Y, Nagane M, Nishikawa R, Ueki K, Aburatani H, Saito N.

Acta Neuropathol Commun. 2017 Mar 7;5(1):18. doi: 10.1186/s40478-017-0422-z.

43.

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.

Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S.

Health Qual Life Outcomes. 2017 Jan 31;15(1):25. doi: 10.1186/s12955-017-0598-8.

44.

Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.

Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, Omata M, Oyama T.

Breast Cancer. 2017 Sep;24(5):667-672. doi: 10.1007/s12282-017-0753-4. Epub 2017 Jan 20.

PMID:
28108967
45.

Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report.

Goto T, Hirotsu Y, Mochizuki H, Nakagomi T, Oyama T, Amemiya K, Omata M.

BMC Cancer. 2017 Jan 19;17(1):65. doi: 10.1186/s12885-017-3059-1.

46.

Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report.

Nakagomi H, Hirotsu Y, Amemiya K, Nakada H, Inoue M, Mochizuki H, Oyama T, Omata M.

Am J Case Rep. 2017 Jan 9;18:26-32.

47.

Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient.

Hirotsu Y, Nakagomi H, Amemiya K, Oyama T, Inoue M, Mochizuki H, Omata M.

Med Oncol. 2017 Jan;34(1):3. Epub 2016 Nov 29.

PMID:
27900589
48.

Biliary cancer developed after the reparative surgery for congenital choledochal cyst: a case report and review of the literature.

Ikegame K, Takano A, Watanabe H, Yamamoto A, Miyasaka Y, Furuya K, Nakada H, Sugai H, Yasutome M, Inoue M, Hada M, Nakagomi H, Omata M, Oyama T.

Int Cancer Conf J. 2016 Nov 12;6(2):43-49. doi: 10.1007/s13691-016-0270-x. eCollection 2017 Apr.

49.
50.

Report of a case with gallbladder carcinoma: P53 expression of the peritumor epithelium might predict biliary tract recurrence.

Takano A, Nakagomi H, Ikegame K, Yamamoto A, Watanabe H, Nakada H, Inoue M, Sugai H, Yasutome M, Furuya K, Hada M, Miyasaka Y, Oyama T, Omata M.

Int J Surg Case Rep. 2016;28:325-329. doi: 10.1016/j.ijscr.2016.10.042. Epub 2016 Oct 18.

Supplemental Content

Support Center